Leerink Partners Maintains Market Perform on Myriad Genetics, Raises Price Target to $8
Benzinga Newsdesk 9 hours ago
Analyst RatingsNewsPrice Target
Leerink Partners analyst Puneet Souda maintains Myriad Genetics (NASDAQ:MYGN) with a Market Perform and raises the price target from $5 to $8.
Leerink Partners analyst Puneet Souda maintains Myriad Genetics (NASDAQ:MYGN) with a Market Perform and raises the price target from $5 to $8.